Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.36 |
| ▸ | BACE1 | P56817 | 13/20 | 0.33 |
| ▸ | APP | P05067 | 6/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.33 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.32 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15469465 | 0.89 | BACE1 (0.32) | BACE1APPAKR1B10AKR1C4AKR1C3 | |
| SCHEMBL15469480 | 0.89 | BACE1 (0.34) | MAP3K14BACE1APPAKR1B10AKR1C4 | |
| SCHEMBL15469489 | 0.85 | BACE1 (0.36) | BACE1APPCYP2D6BACE2AKR1B10 | |
| SCHEMBL15469386 | 0.83 | TRPM8 (0.33) | MAP3K14BACE1APPAKR1B10AKR1C4 | |
| SCHEMBL15469414 | 0.83 | TRPM8 (0.33) | MAP3K14BACE1APPAKR1B10AKR1C4 | |
| SCHEMBL15469470 | 0.82 | BACE1 (0.34) | MAP3K14BACE1APPAKR1B10AKR1C4 | |
| SCHEMBL15467339 | 0.81 | PDE2A (0.35) | — | |
| SCHEMBL15467340 | 0.81 | PDE2A (0.35) | — | |
| SCHEMBL15469474 | 0.79 | SLC6A3 (0.33) | BACE1AKR1B10AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL15469477 | 0.78 | AKR1B10 (0.35) | BACE1APPAKR1B10AKR1C4AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | MAP3K14 1097/4885BACE1 2029/4885APP 1623/4885 |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | MAP3K14 1097/4885BACE1 2029/4885APP 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.